Publications

  1. Falde SD, Lal A, Cartin-Ceba R, Mertz LE, Fervenza FC, Zand L, Koster MJ, Warrington KJ, Lee AS, Aslam N, Abril A, Specks U. Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Diffuse Alveolar Hemorrhage With Avacopan. ACR Open Rheumatol. 2024 Oct; 6 (10):707-716 Epub 2024 July 30
    View PubMed
  2. Sharma S, Shamy OE, Wilmington A, Keller B, Aslam N, Tran H, Rutherford P, Uribarri J. Performance Evaluation of an Automated Peritoneal Dialysis Solution Generation System in Patients Using Automated Peritoneal Dialysis. Kidney Int Rep. 2024 Jun; 9 (6):1752-1757 Epub 2024 Mar 18
    View PubMed
  3. Sullivan MM, Abril A, Aslam N, Ball CT, Berianu F. Nailfold videocapillaroscopy in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Res Ther. 2024 Jan 2; 26 (1):4 Epub 2024 Jan 02
    View PubMed
  4. Lieske JC, Leung N, Erickson SB, Garg P, Rao P, Jain N, Thomas L, Li T, Levin A, Sethi S, Barbour SJ, Fervenza FC, Induruwage D, Brenchley PE, Rovin B, Hladunewich MA, Reich HN, Lafayette R, Aslam N, Appel GB, Zand L, Kiryluk K, Liu L, Cattran DC, MENTOR Trial Investigators. Anti-PLA2R Antibody Levels and Clinical Risk Factors for Treatment Nonresponse in Membranous Nephropathy. Clin J Am Soc Nephrol. 2023 Oct 1; 18 (10):1283-1293 Epub 2023 July 20
    View PubMed
  5. Trautman CL, Khan M, Baker LW, Aslam N, Fitzpatrick P, Porter I 2nd, Mao M, Wadei H, Ball CT, Hickson LJ. Kidney Outcomes Following Utilization of Molecular Adsorbent Recirculating System. Kidney Int Rep. 2023 Oct; 8 (10):2100-2106 Epub 2023 Aug 12
    View PubMed
  6. Khosla AA, Saunders H, Helgeson S, Hikida H, Aslam N, Salem F, Albadri S, Baig H. The Utility of Bronchoscopy in Hydralazine-Induced ANCA-Associated Vasculitis. Case Rep Pulmonol. 2023; 2023:1461011. Epub 2023 Apr 15.
    View PubMed
  7. Roth D, Segal MS, Sastry AD, Aslam N. Organizing Nephrologists at the State Level: The Florida Experience. Clin J Am Soc Nephrol. 2023 Jan 1; 18 (1):124-126
    View PubMed
  8. Schlaich MP, Bellet M, Weber MA, Danaietash P, Bakris GL, Flack JM, Dreier RF, Sassi-Sayadi M, Haskell LP, Narkiewicz K, Wang JG, PRECISION investigators. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet. 2022 Dec 3; 400 (10367):1927-1937 Epub 2022 Nov 07
    View PubMed
  9. Danaietash P, Verweij P, Wang JG, Dresser G, Kantola I, Lawrence MK, Narkiewicz K, Schlaich M, Bellet M, PRECISION investigators. Identifying and treating resistant hypertension in PRECISION: A randomized long-term clinical trial with aprocitentan. J Clin Hypertens (Greenwich). 2022 Jul; 24 (7):804-813 Epub 2022 June 09
    View PubMed
  10. Provenzano M, Jongs N, Vart P, Stefansson BV, Chertow GM, Langkilde AM, McMurray JJV, Correa-Rotter R, Rossing P, Sjostrom CD, Toto RD, Wheeler DC, Heerspink HJL, DAPA-CKD Trial Committees and Investigators . The Kidney Protective Effects of the Sodium-Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists. Kidney Int Rep. 2022 Mar; 7 (3):436-443 Epub 2021 Dec 14
    View PubMed
  11. Heerspink HJL, Cherney D, Postmus D, Stefansson BV, Chertow GM, Dwyer JP, Greene T, Kosiborod M, Langkilde AM, McMurray JJV, Correa-Rotter R, Rossing P, Sjostrom CD, Toto RD, Wheeler DC, DAPA-CKD Trial Committees and Investigators. A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. Kidney Int. 2022 Jan; 101 (1):174-184 Epub 2021 Sept 22
    View PubMed
  12. Bui A, Cortese C, Aslam N. Sarcoidosis-associated renal AA amyloidosis and crescentic necrotizing glomerulonephritis. Proc (Bayl Univ Med Cent). 2022; 35 (5):680-682 Epub 2022 May 16
    View PubMed
  13. Bui A, Butts EB, Aslam N. 47-Year-Old Woman With Bilateral Flank Pain. Mayo Clin Proc. 2021 Dec; 96 (12):3147-3152
    View PubMed
  14. Wheeler DC, Jongs N, Stefansson BV, Chertow GM, Greene T, Hou FF, Langkilde AM, McMurray JJV, Rossing P, Nowicki M, Wittmann I, Correa-Rotter R, Sjostrom CD, Toto RD, Heerspink HJL, DAPA-CKD Trial Committees and Investigators. Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: A prespecified analysis of the DAPA-CKD trial. Nephrol Dial Transplant. 2021 Nov 25 [Epub ahead of print]
    View PubMed
  15. Heerspink HJL, Jongs N, Chertow GM, Langkilde AM, McMurray JJV, Correa-Rotter R, Rossing P, Sjostrom CD, Stefansson BV, Toto RD, Wheeler DC, Greene T, DAPA-CKD Trial Committees and Investigators. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021 Nov; 9 (11):743-754 Epub 2021 Oct 04
    View PubMed
  16. Jongs N, Greene T, Chertow GM, McMurray JJV, Langkilde AM, Correa-Rotter R, Rossing P, Sjostrom CD, Stefansson BV, Toto RD, Wheeler DC, Heerspink HJL, DAPA-CKD Trial Committees and Investigators. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021 Nov; 9 (11):755-766 Epub 2021 Oct 04
    View PubMed
  17. McMurray JJV, Wheeler DC, Stefansson BV, Jongs N, Postmus D, Correa-Rotter R, Chertow GM, Hou FF, Rossing P, Sjostrom CD, Solomon SD, Toto RD, Langkilde AM, Heerspink HJL, DAPA-CKD Trial Committees and Investigators. Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure. JACC Heart Fail. 2021 Nov; 9 (11):807-820 Epub 2021 Aug 23
    View PubMed
  18. Baker LW, Jimenez-Lopez J, Geiger XJ, Aslam N. Malignancy-Associated Membranous Nephropathy with Positive Anti-PLA2R Autoantibodies: Coincidence or Connection. Case Rep Nephrol Dial. 2021 Sep-Dec; 11 (3):334-339 Epub 2021 Nov 18
    View PubMed
  19. Chertow GM, Vart P, Jongs N, Toto RD, Gorriz JL, Hou FF, McMurray JJV, Correa-Rotter R, Rossing P, Sjostrom CD, Stefansson BV, Langkilde AM, Wheeler DC, Heerspink HJL, DAPA-CKD Trial Committees and Investigators. Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease. J Am Soc Nephrol. 2021 Sep; 32 (9):2352-2361 Epub 2021 July 16
    View PubMed
  20. Persson F, Rossing P, Vart P, Chertow GM, Hou FF, Jongs N, McMurray JJV, Correa-Rotter R, Bajaj HS, Stefansson BV, Toto RD, Langkilde AM, Wheeler DC, Heerspink HJL, DAPA-CKD Trial Committees and Investigators. Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial. Diabetes Care. 2021 Aug; 44 (8):1894-1897 Epub 2021 June 28
    View PubMed
  21. Aslam N, Trautman CL, Sher T. Kidney Transplantation and Monoclonal Gammopathy of Undetermined Significance. Transplant Direct. 2021 Aug; 7 (8):e723 Epub 2021 July 09
    View PubMed
  22. Niazi SK, Memon SH, Lesser ER, Brennan E, Aslam N. Assessment of psychiatric comorbidities and serotonergic or noradrenergic medication use on blood pressure using 24-hour ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2021 Aug; 23 (8):1599-1607 Epub 2021 June 29
    View PubMed
  23. Aslam N, Memon SH, Wadei H, Lesser ER, Niazi SK. Utility of 24-hour ambulatory blood pressure monitoring in potential living kidney donors. Clin Hypertens. 2021 Jul 1; 27 (1):13 Epub 2021 July 01
    View PubMed
  24. Wheeler DC, Toto RD, Stefansson BV, Jongs N, Chertow GM, Greene T, Hou FF, McMurray JJV, Pecoits-Filho R, Correa-Rotter R, Rossing P, Sjostrom CD, Umanath K, Langkilde AM, Heerspink HJL. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 2021 Jul; 100 (1):215-224 Epub 2021 Apr 18
    View PubMed
  25. Sethi A, Miao J, Willrich MAV, Frinack JL, Cattran DC, Fervenza FC, MENTOR study Investigators//MENTOR study investigators. Limited Significance of Antifactor H Antibodies in Patients with Membranous Nephropathy. Clin J Am Soc Nephrol 2021 Jun; 16 (6):939-941 Epub 2021 Apr 15
    View PubMed
  26. Heerspink HJL, Sjostrom CD, Jongs N, Chertow GM, Kosiborod M, Hou FF, McMurray JJV, Rossing P, Correa-Rotter R, Kurlyandskaya R, Stefansson BV, Toto RD, Langkilde AM, Wheeler DC. Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial. Eur Heart J. 2021 Mar 31; 42 (13):1216-1227
    View PubMed
  27. Baker LW, Khan M, Cortese C, Aslam N. Fibrillary glomerulonephritis or complement 3 glomerulopathy: a rare case of diffuse necrotising crescentic glomerulonephritis with C3-dominant glomerular deposition and positive DNAJB9. BMJ Case Rep. 2021 Feb 18; 14 (2)
    View PubMed
  28. Wheeler DC, Stefansson BV, Jongs N, Chertow GM, Greene T, Hou FF, McMurray JJV, Correa-Rotter R, Rossing P, Toto RD, Sjostrom CD, Langkilde AM, Heerspink HJL. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021 Jan; 9 (1):22-31
    View PubMed
  29. McMurray JJV, Wheeler DC, Stefansson BV, Jongs N, Postmus D, Correa-Rotter R, Chertow GM, Greene T, Held C, Hou FF, Mann JFE, Rossing P, Sjostrom CD, Toto RD, Langkilde AM, Heerspink HJL. Effect of Dapagliflozin on Clinical Outcomes in Patients with Chronic Kidney Disease, With and Without Cardiovascular Disease. Circulation. 2020 Nov 13 [Epub ahead of print]
    View PubMed
  30. Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjostrom CD, Toto RD, Langkilde AM, Wheeler DC. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020 Oct 8; 383 (15):1436-1446 Epub 2020 Sept 24
    View PubMed
  31. Aslam N, Govani M, Basdeo LM, Wadei HM. Can ferric citrate lead to iron overload in peritoneal dialysis patients?. Clin Nephrol. 2020 May; 93 (5):262-266
    View PubMed
  32. Heerspink HJL, Stefansson BV, Chertow GM, Correa-Rotter R, Greene T, Hou FF, Lindberg M, McMurray J, Rossing P, Toto R, Langkilde AM, Wheeler DC. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrol Dial Transplant. 2020 Feb 1; 35 (2):274-282
    View PubMed
  33. Trautman C, Da Costa JR, Cortese C, Aslam N. Prosthetic valve endocarditis from Mycobacterium chimaera infection causing granulomatous interstitial nephritis. IDCases. 2020; 20:e00733 Epub 2020 Feb 27
    View PubMed
  34. Zand L, Canetta P, Lafayette R, Aslam N, Jan N, Sethi S, Fervenza FC. An Open-Label Pilot Study of Adrenocorticotrophic Hormone in the Treatment of IgA Nephropathy at High Risk of Progression. Kidney Int Rep. 2020 Jan; 5 (1):58-65 Epub 2019 Oct 31
    View PubMed
  35. Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA, Aslam N, Jefferson JA, Gipson PE, Rizk DV, Sedor JR, Simon JF, McCarthy ET, Brenchley P, Sethi S, Avila-Casado C, Beanlands H, Lieske JC, Philibert D, Li T, Thomas LF, Green DF, Juncos LA, Beara-Lasic L, Blumenthal SS, Sussman AN, Erickson SB, Hladunewich M, Canetta PA, Hebert LA, Leung N, Radhakrishnan J, Reich HN, Parikh SV, Gipson DS, Lee DK, da Costa BR, Juni P, Cattran DC, MENTOR Investigators. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. N Engl J Med. 2019 Jul 4; 381 (1):36-46
    View PubMed
  36. Kroner PT, Mareth K, Raimondo M, Lee DD, Alsaad A, Aslam N, Abader P, Wadei HM. Acute Pancreatitis in Advanced Chronic Kidney Disease and Kidney Transplant Recipients: Results of a US Nationwide Analysis. Mayo Clin Proc Innov Qual Outcomes. 2019 Jun; 3 (2):160-168 Epub 2019 May 27
    View PubMed
  37. Aslam N, Missick S, Haley W. Ambulatory Blood Pressure Monitoring: Profiles in Chronic Kidney Disease Patients and Utility in Management. Adv Chronic Kidney Dis. 2019 Mar; 26 (2):92-98
    View PubMed
  38. Aslam N, Singh A, Cortese C, Riegert-Johnson DL. A novel variant in FN1 in a family with fibronectin glomerulopathy. Hum Genome Var. 2019; 6:11 Epub 2019 Feb 27
    View PubMed
  39. Missick S, Aslam N. Hypercalcemia, Acute Kidney Injury, and Esophageal Lymphadenopathy. Am J Kidney Dis. 2018 Jul; 72 (1):A13-A15
    View PubMed
  40. Leonard D, Cortese C, Wadei HM, Porter II IE II, Aslam N. Behcet's syndrome and focal segmental glomerulosclerosis with nephrotic syndrome - successful treatment with etanercept. Clin Nephrol. 2018 May; 89 (5):371-375
    View PubMed
  41. Thom T, Leonard D, Fitzpatrick P, Aslam N. Transection versus infection: acute appendicitis in a peritoneal dialysis patient presenting as catheter dysfunction and discontinuity on X-ray. BMJ Case Rep. 2018 Apr 17; 2018
    View PubMed
  42. Ailawadhi S, Frank RD, Sharma M, Menghani R, Temkit M, Paulus S, Khera N, Hashmi S, Advani P, Swaika A, Paulus A, Aslam N, Sher T, Roy V, Colon-Otero G, Chanan-Khan A. Trends in multiple myeloma presentation, management, cost of care, and outcomes in the Medicare population: A comprehensive look at racial disparities. Cancer. 2018 Apr 15; 124 (8):1710-1721 Epub 2018 Jan 23
    View PubMed
  43. Hines SL, Agarwal A, Ghandour M, Aslam N, Mohammad AN, Atwal PS. Novel variants in COL4A4 and COL4A5 are rare causes of FSGS in two unrelated families. Hum Genome Var. 2018; 5:15 Epub 2018 July 10
    View PubMed
  44. Hines SL, Agarwal A, Ghandour M, Aslam N, Mohammad AN, Atwal PS. Correction: Novel variants in COL4A4 and COL4A5 are rare causes of FSGS in two unrelated families. Hum Genome Var. 2018; 5:24 Epub 2018 Aug 28
    View PubMed
  45. Abadeer K, Aslam N, Cortese C, Wadei HM. Cytomegalovirus-Induced Polyarteritis Nodosa in a Liver Transplant Recipient. Am J Transplant. 2017 Dec; 17 (12):3236-3240 Epub 2017 June 30
    View PubMed
  46. Daniels MN, Maynard S, Porter I, Kincaid H, Jain D, Aslam N. Career interest and perceptions of nephrology: A repeated cross-sectional survey of internal medicine residents. PLoS One. 2017; 12 (2):e0172167 Epub 2017 Feb 16
    View PubMed
  47. Aslam N. Chronic Kidney Disease - An Update Northeast Florida Medicine.2016;67:(2):28-32.
  48. Fervenza FC, Canetta PA, Barbour SJ, Lafayette RA, Rovin BH, Aslam N, Hladunewich MA, Irazabal MV, Sethi S, Gipson DS, Reich HN, Brenchley P, Kretzler M, Radhakrishnan J, Hebert LA, Gipson PE, Thomas LF, McCarthy ET, Appel GB, Jefferson JA, Eirin A, Lieske JC, Hogan MC, Greene EL, Dillon JJ, Leung N, Sedor JR, Rizk DV, Blumenthal SS, Lasic LB, Juncos LA, Green DF, Simon J, Sussman AN, Philibert D, Cattran DC, Mentor Consortium group. A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR). Nephron. 2015; 130 (3):159-68 Epub 2015 June 12
    View PubMed
  49. Palevsky PM, Zhang JH, O'Connor TZ, Chertow GM, Crowley ST, Choudhury D, Finkel K, Kellum JA, Paganini E, Schein RM, Smith MW, Swanson KM, Thompson BT, Vijayan A, Watnick S, Star RA, Peduzzi P, VA/NIH Acute Renal Failure Trial Network. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med. 2008 Jul 3; 359 (1):7-20 Epub 2008 May 20
    View PubMed
  50. Crowley ST, Chertow GM, Vitale J, O'Connor T, Zhang J, Schein RM, Choudhury D, Finkel K, Vijayan A, Paganini E, Palevsky PM, VA/NIH Acute Renal Failure Trial Network Study Group. Lessons for successful study enrollment from the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. Clin J Am Soc Nephrol. 2008 Jul; 3 (4):955-61 Epub 2008 Apr 02
    View PubMed
  51. Aslam N, Bernardini J, Fried L, Burr R, Piraino B. Comparison of infectious complications between incident hemodialysis and peritoneal dialysis patients. Clin J Am Soc Nephrol. 2006 Nov; 1(6):1226-33. Epub 2006 Oct 11.
    View PubMed
  52. Aslam N, Pasacreta M, Bastacky SI, McHale T, Huston A, Palevsky PM, Weisbord SD. Light chain-associated Fanconi syndrome with nephrotic range proteinuria Am J Kidney Dis.2006;47:(4:A57):e43-5.
    View PubMed
  53. Enoch C, Aslam N, Piraino B. Intra-abdominal pressure, peritoneal dialysis exchange volume, and tolerance in APD Semin Dial..2005;15:(6):403-6.
    View PubMed
  54. Aslam N, Bernardini J, Fried L, Piraino B. Large body mass index does not predict short-term survival in peritoneal dialysis patients. Perit Dial Int. 2002 Mar-Apr; 22(2):191-6.
    View PubMed
  55. Aslam N, Bernardini J, Fried L, Piraino B. Peritoneal dialysis clearance can replace residual renal function. Perit Dial Int. 2001 May-Jun; 21(3):263-8.
    View PubMed
  56. Holley JL, Aslam N, Bernardini J, Fried L, Piraino B. The influence of demographic factors and modality on loss of residual renal function in incident peritoneal dialysis patients. Perit Dial Int. 2001 May-Jun; 21(3):302-5.
    View PubMed
  57. Aslam N, Palevsky PM. Insertion of dialysis catheters with the aid of real-time ultrasound Saudi J Kidney Dis Transplant.2001;12:(3):375-381.
    View PubMed
  58. Aslam N, Nseir N I, Viverett J F, Bastacky S I, Johnson J P. Nephrotic syndrome in chronic lymphocytic leukemia. A Paraneoplastic syndrome? Clin. Nephrology.2000;54:(6):492-497.
    View PubMed
  59. Aslam N, Palevsky P. Use of real-time ultrasound for placement of hemodialysis catheters: A new standard of care Seminars in Dialysis. 1999; 12(1):1-4.